Prosetta Biosciences, Inc.
Prosetta Biosciences is a San Francisco-based biotechnology company focused on creating innovative therapeutics for diseases by identifying and advancing novel small molecules that modulate the assembly of multi-protein complexes within cells. Their technology aims to work in tandem with the body's regulatory mechanisms to restore molecular homeostasis, offering a new strategy for treating various diseases including infectious, degenerative, and neurodegenerative disorders.
Industries
Nr. of Employees
small (1-50)
Prosetta Biosciences, Inc.
San Francisco, California, United States, North America
Products
Cell-free protein synthesis and assembly screening platform
A converted academic cell-free protein synthesis and assembly (CFPSA) assay into a moderate-throughput screening platform for identifying small molecules that modulate multiprotein assembly.
Hit-finder assembly-modulator compound collection
A curated collection of structurally diverse small molecules (reported ~300) derived from screening that share assembly-modulating properties and are used to probe host assembly pathways and advance lead series.
Pan-respiratory antiviral program (lead series)
Discovery and preclinical advancement of small-molecule chemotypes active across multiple virus families that cause human respiratory disease; reported activity in human airway epithelial cultures and animal models.
HIV assembly-modulation program
Preclinical discovery of multiple small-molecule chemotypes that target host-dependent steps in HIV capsid assembly or post-entry capsid disassembly, producing effects such as redirected proteasomal degradation, release of non-infectious particles, or blocking infection prior to gene expression.
Neuroscience programs (ALS, Alzheimer’s, Parkinson’s)
Application of assembly-modulating small molecules to cellular and animal models of neurodegenerative disease, including compounds that relocalize TDP-43, reduce tau hyperphosphorylation, or modulate alpha-synuclein assembly; includes development of peripheral biomarker assays for ALS.
Oncology pan-cancer assembly-modulator program
Discovery and preclinical exploration of small-molecule series with reported anti-proliferative activity across a broad panel of cancer cell types.
Cell-free protein synthesis and assembly screening platform
A converted academic cell-free protein synthesis and assembly (CFPSA) assay into a moderate-throughput screening platform for identifying small molecules that modulate multiprotein assembly.
Hit-finder assembly-modulator compound collection
A curated collection of structurally diverse small molecules (reported ~300) derived from screening that share assembly-modulating properties and are used to probe host assembly pathways and advance lead series.
Pan-respiratory antiviral program (lead series)
Discovery and preclinical advancement of small-molecule chemotypes active across multiple virus families that cause human respiratory disease; reported activity in human airway epithelial cultures and animal models.
HIV assembly-modulation program
Preclinical discovery of multiple small-molecule chemotypes that target host-dependent steps in HIV capsid assembly or post-entry capsid disassembly, producing effects such as redirected proteasomal degradation, release of non-infectious particles, or blocking infection prior to gene expression.
Neuroscience programs (ALS, Alzheimer’s, Parkinson’s)
Application of assembly-modulating small molecules to cellular and animal models of neurodegenerative disease, including compounds that relocalize TDP-43, reduce tau hyperphosphorylation, or modulate alpha-synuclein assembly; includes development of peripheral biomarker assays for ALS.
Oncology pan-cancer assembly-modulator program
Discovery and preclinical exploration of small-molecule series with reported anti-proliferative activity across a broad panel of cancer cell types.
Services
Collaborative drug-discovery partnerships
Research collaborations and partnerships to advance discovery and preclinical development of assembly-modulating small-molecule programs.
Collaborative drug-discovery partnerships
Research collaborations and partnerships to advance discovery and preclinical development of assembly-modulating small-molecule programs.
Expertise Areas
- Host-targeted small-molecule drug discovery
- Cell-free assay development and screening
- Proteomics-driven target identification
- Preclinical in vitro and in vivo validation
Key Technologies
- Cell-free protein synthesis and assembly (CFPSA)
- Moderate-throughput small-molecule screening
- Drug-resin affinity chromatography (DRAC)
- Mass spectrometry proteomics (MS-MS)